Morningstar analysts upgraded Insulet Corp.’s (NSDQ:PODD) credit rating from a CCC to a B- today, reflecting the company’s recent convertible debt offering, but the company will have to face off against medical device giant Medtronic Inc. (NYSE:MDT) in the insulin delivery market. Insulet announced a double offering of convertible senior notes and common stock late last month, on the heels of its $63 million acquisition of Neighborhood Diabetes Inc. The offerings could yield more than $130 million together.
